The addition of Monroe as CFO will support corporate structuring efforts and position the company for the next phase of rapid growth

CFO Alex Monroe

CHARLOTTE, N.C. – October 18, 2022 – (Newswire.com)

Let’s Talk Interactive, Inc. (LTI), an innovator in telehealth solutions, has announced the addition of Alexander Monroe as its Chief Financial Officer. As a seasoned executive with proven leadership experience in finance, corporate strategy and corporate development, Monroe will be a key asset for LTI as it prepares for its next stage of accelerated growth.

“As we continue to lead in the field of virtual healthcare, it’s essential that we position ourselves well for any market conditions,” said Arthur Cooksey, founder, Chairman, and CEO of Let’s Talk Interactive. “Alexander brings a wealth of experience that will be a significant asset as LTI continues on its trajectory of rapid infrastructure and development growth through capital raise to support continued innovation and expansion into manufacturing.”

Monroe began his career in investment banking doing middle-market mergers and acquisitions. After leaving investment banking, he transitioned to the corporate sector, during which he led the corporate development groups of two Fortune 500 companies, overseeing strategic development and business development functions.

Seeing a significant need in the marketplace, he left the corporate sector and founded and built a global consumer products company, which he later sold. The sale would be the springboard that allowed Monroe to pursue his passion for working closely with small and midsize businesses, helping them to achieve big company sophistication and expertise while maintaining the culture and nimbleness of a small company. This is when he began working as the CFO of a global government security contractor. As its CFO, he led the recapitalization and restructuring of the company to position it for sustainable and profitable growth. He was eventually promoted to the company’s President and CEO, during which he orchestrated the most profitable 12-month period in the company’s history, positioning the company for sale and ultimately successfully selling the company to a strategic buyer.

“I believe LTI’s telehealth solutions meet a critical need within the marketplace. Coming from a family full of physicians, I understand the massive inefficiencies LTI’s solutions address and solve within healthcare,” said Monroe. “I’m excited to be working alongside the most talented, experienced team in virtual care and look forward to helping the LTI reach new levels of success.”

Monroe holds a Master of Business Administration (MBA) in International Finance from the Thunderbird School of Global Management. To learn more about Let’s Talk Interactive, Inc., visit https://letstalkinteractive.com/. 

About Let’s Talk Interactive, Inc.

Let’s Talk Interactive, Inc. (LTI) is an innovator in telehealth that has developed the most complete and configurable HIPAA-compliant telemedicine platform in the world.  

Through proprietary telehealth software, medical hardware, and provider network solutions, LTI gives those in need instant access to care. Headquartered in Charlotte, North Carolina, the company ranked No. 496 on the 2022 Inc. 5000 annual list of fastest-growing companies. For more information about Let’s Talk Interactive, visit www.letstalkinteractive.com.

Contact Information:

Caitlin Wolf

PR and Communications Executive

caitlin@letstalkinteractive.com

980-220-3777

Press Release Service
by
Newswire.com

Original Source:

Let’s Talk Interactive Brings in Chief Financial Officer Alexander Monroe

Great emphasis on passenger safety and cabin comfort, coupled with efficient and electrified powertrains. This is a brief description of Volvo’s market strategy in 2022. Is it the winning formula? Only the future sales numbers will tell, but for now let’s explore the latest improvements to the lineup and all-new models with the iconic Scandinavian […]

The most important venues, amenities, and restaurants onboard the Oasis of the Seas for an Atlantis gay cruise! More gay cruise advice: 00:00 Intro 00:45 DECK 4 00:47 Royal Theater 01:09 Studio B 01:44 Main Dining Hall 02:09 DECK 5 02:18 Guest Services 02:40 Sorrento’s 02:48 Cafe Promenade 03:05 Rising Tide bar 03:19 Bionic bar […]

The post Oasis of the Seas Ship Tour! Atlantis 2022 Oasis Cruise | JustJoeyT #Gay #Cruise #Advice first appeared on Miami In News.

The wireless, long-duration, continuous, ultrasound, patch-based stimulator delivers 33 times more treatment than pulsed ultrasound devices and is authorized by the FDA for prescription home use in the United States of…

The Disruptive Intelligent Automation Platform adds Visibility to Security with Multiple Certifications

The OpenBots Team OpenBots attended the B…

The Wake Forest Demon Deacons went into Tallahassee and came away with a 31-21 win over the Seminoles. Wake running back Justice Ellison carried 18 times for 114 yards and a touchdown and Christian Turner added 64 yards and a touchdown. Deacons quarterback Sam Hartman passed for 234 yards and 2 touchdowns in the win. […]

These American Heart Association courses offer a flexible and affordable way to earn CPR, BLS, ACLS, and PALS certification. Safety Training Seminars offers these courses every day of the week – including Saturdays and…

Partnership Extends to all 29 Exer Urgent Care Locations Throughout Southern California

Intend, Inc. intend tm logo
FULLERTON,…

World-ranked powerlifter Robyn Machado praises Stirling’s Delta 8 Sleep gummies and Magnesium Balm for their ability to alleviate pain and soreness from training

CARY, N.C. – October 17, 2022 – (Newswire.com)

After more than 20 years of lifting weights and seven years as a competitive powerlifter, Robyn Machado knows what is needed to stay in top shape, and Stirling CBD’s line of products are her go-to aid for recovery and alleviating pain during training.

Machado, 36, was ranked in the top 10 worldwide in the 60-kilo class. Now competing in the 67.5-kilo class, she was recently ranked 15th in the world. Stirling CBD’s Delta 8 Sleep gummies and Magnesium Balm are key elements of her training. The Delta 8 gummies help Machado stay calm and relaxed without any adverse effects, while the magnesium balm on joints and sore muscles helps alleviate pain and soreness and speed up the healing process.

“When it comes to training, keeping stress to a minimum is optimal, so I use the Magnesium Balm during the day, which helps with inflammation,” said Machado. “But I also train at night, so Delta 8 Sleep Gummies are key in helping me wind down after a workout and to allow me to chill out and get a great night’s sleep. A good night’s sleep is critical to a powerlifter, and Stirling’s gummies help me fall asleep and stay asleep. I wake up feeling refreshed and ready to go.”

Machado regularly sees Dr. Matt Arthur at 919Spine, who recommended the Stirling CBD products and introduced her to Stirling CBD President Joe Kryszak. “I love Stirling’s products. They have really had a positive impact on my training and recovery,” she said. “I’ve tried similar products, but the levels of CBD were too inconsistent. With Stirling, I know I’m getting consistency and the highest-quality product available. They show third party certificates of analysis of each product right on their webpage, so I know exactly what is going into my body.”

CBD Muscle Gel is another lotion that Machado is a big fan of. The Muscle Gel has capsaicin, camphor and menthol, which creates an invigorating cold-hot sensation that helps blood flow in the muscle and joints. In addition, the aloe vera, black pepper extract, and witch hazel ingredients combine for a great solution for pre- and post-workout.

Designed to help alleviate joint pain, Stirling’s CBD lotions are among the most powerful lotions on the market. In addition, all of Stirling’s CBD lotions, gels, and balms are non-GMO-produced, organic, THC-free, vegan, free from additives and chemicals, and are never tested on animals.

For more information, please visit https://www.stirlingcbdoil.com

Contact Information:

Mike Albanese

mike.albanese@newswire.com

Related Images

Press Release Service
by
Newswire.com

Original Source:

Stirling CBD Products Help Competitive Powerlifter in Her Training and Recovery

The Optejet® ophthalmic drug device is designed to precisely administer medication to the eye, potentially treating patients’ conditions through gentler, more efficient dosing.

Optejet
Optejet

NEW YORK – October 17, 2022 – (Newswire.com)

Two recent studies show that the novel Optejet® dispenser from Eyenovia, Inc., an ophthalmic pharmaceutical technology company, may be a more “human-centric” design than traditional eye droppers, which may make treatments for vision problems, including myopia, presbyopia and mydriasis, easier to deliver. 

The investigational Optejet® dispenser administers ophthalmic solutions horizontally using the company’s proprietary Microdose Array Print (MAP™) technology. The system has been shown to deliver accurate microdoses through a precision spray, dispensing medication with the push of a button, with no need to tilt the head back, and requires minimal hand-eye coordination.

Traditional eye drops can deliver four to five times larger volumes of medication than the human eye can hold, which can cause overdosing and drug waste. The Optejet® dispenser is designed to administer 1/5 the volume of solution compared to a traditional eyedropper, making doses less likely to spill or run onto the patient’s face.

“Traditional eye drops typically overdose a patient’s eye with medication and preservatives, which can lead to significant dose-related side effects,” said Michael Rowe, CEO of Eyenovia. “Optejet® is proving to be easier to use and therefore may deliver the appropriate dose of medication to potentially decrease side effects.” 

One paper (Rathi, Scott, 2020) presented at the 2020 American Society of Cataract and Refractive Surgery reviewed multiple studies comparing the Optejet® dispenser with traditional eye droppers. In one study with the Optejet®, the researcher successfully administered 96% of doses on the first attempt, and 95% of patients successfully self-administered the doses on the first attempt as well. Another study found ophthalmic technicians successfully delivered doses on 83% of first attempts and were successful 99% of the time within two attempts.

A separate study conducted by Eyenovia (2021) monitored the six-month daily eye drop treatment compliance of 28 children ages 6 to 13 with pediatric progressive myopia. It found that nearly 90% of children using the Optejet® once-daily treatment successfully complied with their treatment regimen. This compares favorably to the 50% compliance rate for pediatric ophthalmic medications or the 59-69% range for adult topical ophthalmic drug users (Naito, 2018; see also Patel, 1995; Winfield, 1990; Matsui, 1997).

The unique delivery mechanism of the Optejet® has the potential to fundamentally change how people think about administering eye medication. Of 100 presbyopic patients between the ages of 40-55, four out of five said they would prefer using the investigational Optejet® device over traditional eye drops, according to a survey conducted by Eyenovia.

Optejet® has not been approved, cleared, or licensed by the U.S. Food and Drug Administration for use, and it is not commercially available in the United States. For more information about the Optejet® device, visit eyenovia.com.

About Eyenovia, Inc.

Eyenovia, Inc. is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP^TM) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit www.eyenovia.com. 

Forward-Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19), timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential impacts of COVID-19 on our supply chain; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws. Eyenovia does not undertake any obligation to update any forward-looking statements.

Contact Information:

Norbert Lowe

Vice President, Commercial Operations

nlowe@eyenovia.com

Buse Kayar

buse@newswire.com

Press Release Service
by
Newswire.com

Original Source:

Investigational Optejet® Microdose Dispenser from Eyenovia Shows Promise in Improving Treatment for Myopia, Presbyopia and Patients Getting Eye Exams